Compare USNA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | FHTX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 323.4M |
| IPO Year | 1996 | 2020 |
| Metric | USNA | FHTX |
|---|---|---|
| Price | $22.08 | $5.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 107.6K | ★ 366.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | $30,909,000.00 |
| Revenue This Year | $3.90 | $8.89 |
| Revenue Next Year | $6.21 | $20.13 |
| P/E Ratio | $53.73 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $16.60 | $3.27 |
| 52 Week High | $38.32 | $6.95 |
| Indicator | USNA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 68.76 |
| Support Level | $18.71 | $4.37 |
| Resistance Level | $22.71 | $6.95 |
| Average True Range (ATR) | 0.86 | 0.43 |
| MACD | 0.15 | 0.18 |
| Stochastic Oscillator | 88.77 | 70.22 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.